W Mark Erwin, DC, PhD Biological Therapy for the Degenerative Disc: youtu.be/uxdoGNhJCC0?a via YouTube

We're pleased to announce the launch of our new website. Visit us at notogen.com #biotech #startup #regenerativemedicine

Therapeutic Potential of NTG-101, a Single Dose Injectable Treatment for Degenerative Disc Disease, Demonstrated in Preclinical Large Animal Study Published in Nature Publishing Group's “Scientific Reports” ow.ly/fZBy30mCrFL Scientific Reports @NatureNews

NTG-101: A Novel Molecular Therapy that Halts the Progression of Degenerative Disc Disease ow.ly/wlyD30mCpL8 Scientific Reports University of Toronto University of Alberta University Health Network

"The findings are supportive of NTG-101 as a means to impede disc degeneration, promote disc regeneration, halt inflammation, and suppress the expression of molecules secreted by discs that are known causes of pain.” -Dr. Mark Erwin #biotech #regenerativemedicine

Notogen Appoints Gary Margolis as New Chief Executive Officer ow.ly/VxfV30mGyS6 #biotech #regenerativemedicine #biologics #drugdevelopment #notogen #NTG101

New CEO, Gary Margolis, believes NTG-101 "has the potential to be a game-changing treatment for disc degeneration disease.” ow.ly/2JDw30mJlqX

Notogen is very pleased to announce that it has entered a worldwide research collaboration and license agreement with Boehringer Ingelheim to develop and commercialize a Notogen regenerative therapeutic for people living with degenerative disc disease. einpresswire.com/article/607927…